Clinical trial · Interventional
Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel
Neoadjuvant Chemotherapy With 3x Epirubicin/Docetaxel Followed by 3x Carboplatin/Docetaxel in Patients With Primary Breast Cancer
NCT00527449CI-TRIAL-00003031ETCat01completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to optimize results in neoadjuvant chemotherapy of local advanced primary breast cancer. Therefore patients become first 3 cycles of Epirubicin/Docetaxel followed by 3x Carboplatin/Docetaxel.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Primary Breast Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epirubicin, Carboplatin, Docetaxel | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Determining pathologic complete remission under study treatment
- timeFrame
- 28 days after last administration of chemotherapy
Secondary outcomes (3)
- measure
- Rate of breast conserving operations
- timeFrame
- 28 days after administration of last chemotherapy
- measure
- Response to treatment
- timeFrame
- 28 days after last administration of chemotherapy
- measure
- Determining the therapy associated toxicity
- timeFrame
- 28 days after last administration of chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically assured breast cancer * age \>= 18 years * bone marrow function: neutrophils \>= 1.5x109/l, platelets \>= 100x109/l, hemoglobin \>=6.2 mmol/l * sufficient renal and liver function * ECOG 0-2 * written informed consent Exclusion Criteria: * pregnant or nursing women * distant metastases * T2-Tumour \< 3cm and G1 * existing motoric or sensoric neurotoxicity \> Grade 2 * known hypersensitivity against Epirubicin or other anthracycline or against Carboplatin or other platin derivatives or against Docetaxel or against substances in the preparing solutions
References
Publications (0)
Data not yet available
No reference posted for this study.